Axon Enterprise (NASDAQ:AXON) Trading Up 6.4% – What’s Next?

Shares of Axon Enterprise, Inc (NASDAQ:AXON) shot up 6.4% during mid-day trading on Wednesday . The stock traded as high as $467.97 and last traded at $470.4250. 1,463,181 shares were traded during trading, an increase of 39% from the average session volume of 1,050,970 shares. The stock had previously closed at $442.08.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon priced $1 billion of 0% convertible senior notes due 2031, with underwriters able to purchase an additional $150 million. The notes carry no cash interest, allowing Axon to raise capital at a low stated financing cost and potentially strengthen its balance sheet for acquisitions, product development and expansion of its public-safety software platform. Axon Announces Pricing of Convertible Notes
• Neutral Sentiment: Analysts and investors remain divided: Axon’s recurring software revenue, connected devices and law-enforcement technology are viewed as strengthening its competitive moat, but commentary emphasizes that the stock’s margin of safety is limited after its premium valuation. Recent quarterly revenue rose 35.3% year over year and exceeded estimates, although earnings declined from the prior-year period. Axon Enterprise Valuation Analysis
• Negative Sentiment: The offering triggered a selloff because convertible notes can ultimately be exchanged for shares, creating potential dilution and an overhang on the stock. Investors also questioned why Axon needed to raise substantial capital, with reports pointing to pressure on cash flow and a desire to replenish its “war chest.” What’s Going On With Axon Shares
• Negative Sentiment: Axon’s elevated earnings multiple makes the stock particularly sensitive to financing and dilution concerns. A reported insider sale of 1,017 shares worth approximately $489,000 added a modest negative signal, although the transaction was executed under a pre-arranged Rule 10b5-1 plan and represents only a small reduction in the insider’s holdings. Axon Insider Sale

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, September 2nd. Barclays lifted their price target on Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a report on Wednesday, August 5th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. Finally, Citizens Jmp reissued a “market outperform” rating and set a $700.00 target price on shares of Axon Enterprise in a report on Thursday, June 25th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $721.57.

Axon Enterprise Trading Up 5.2%

The stock has a market capitalization of $37.80 billion, a P/E ratio of 193.24, a P/E/G ratio of 9.23 and a beta of 1.40. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. The business has a 50-day moving average price of $555.06 and a two-hundred day moving average price of $488.60.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $1.88 EPS for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The business had revenue of $904.39 million during the quarter, compared to the consensus estimate of $876.42 million. During the same quarter in the previous year, the firm earned $2.12 earnings per share. Axon Enterprise’s revenue for the quarter was up 35.3% compared to the same quarter last year. On average, analysts expect that Axon Enterprise, Inc will post 2.12 EPS for the current fiscal year.

Insider Activity

In related news, President Joshua Isner sold 16,775 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the sale, the president owned 296,974 shares in the company, valued at approximately $170,590,774.82. This trade represents a 5.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 1,017 shares of Axon Enterprise stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $480.45, for a total transaction of $488,617.65. Following the completion of the transaction, the insider directly owned 56,264 shares in the company, valued at $27,032,038.80. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 67,397 shares of company stock worth $38,160,884. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors have recently modified their holdings of AXON. Pure Financial Advisors LLC boosted its holdings in shares of Axon Enterprise by 6.7% in the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 23 shares in the last quarter. Keel Point LLC raised its stake in shares of Axon Enterprise by 4.4% during the 1st quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 25 shares in the last quarter. Bridgewater Advisors Inc. lifted its position in Axon Enterprise by 4.4% during the second quarter. Bridgewater Advisors Inc. now owns 616 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 26 shares during the last quarter. Roman Butler Fullerton & Co. lifted its position in Axon Enterprise by 2.4% during the first quarter. Roman Butler Fullerton & Co. now owns 1,278 shares of the biotechnology company’s stock valued at $500,000 after acquiring an additional 30 shares during the last quarter. Finally, 44 Wealth Management LLC boosted its stake in Axon Enterprise by 6.0% in the first quarter. 44 Wealth Management LLC now owns 530 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 30 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and equipment for law enforcement, public safety and other government agencies. Its product portfolio includes TASER energy weapons, body-worn cameras, in-car cameras and related connected devices designed to support safer interactions, improve transparency and collect operational data.

The company also provides cloud-based software for managing digital evidence, conducting investigations, overseeing records and workflows, coordinating dispatch and supporting real-time public safety operations.